Supriya Lifescience receives USFDA EIR with VAI classification for Maharashtra API facility
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Subscribe To Our Newsletter & Stay Updated